Vaccine Therapy in Treating Patients With Melanoma of the Eye

NCT00036816 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

13

Enrollment

NETWORK

Sponsor class

Stopped low accrual

Conditions

Intraocular Melanoma

Interventions

BIOLOGICAL: MART-1 antigen
BIOLOGICAL: NA17-A antigen
BIOLOGICAL: gp100 antigen
BIOLOGICAL: tyrosinase peptide

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC